Immuron Ltd (IMRN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
IMRN Profit Margin, ROE & Profitability Analysis
IMRN vs Healthcare Sector: How Immuron Ltd Compares
How Immuron Ltd compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Immuron Ltd Stock Overvalued? IMRN Valuation Analysis 2026
Based on fundamental analysis, Immuron Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Immuron Ltd Balance Sheet: IMRN Debt, Cash & Liquidity
IMRN Revenue Growth, EPS Growth & YoY Performance
IMRN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Immuron Ltd (CIK: 0001660046)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMRN
What is the AI rating for IMRN?
Immuron Ltd (IMRN) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMRN's key strengths?
Claude: Analysis in progress.
What are the risks of investing in IMRN?
Claude: Analysis in progress.
What is IMRN's revenue and growth?
Immuron Ltd reported revenue of N/A.
Does IMRN pay dividends?
Immuron Ltd does not currently pay dividends.
Where can I find IMRN SEC filings?
Official SEC filings for Immuron Ltd (CIK: 0001660046) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMRN's EPS?
Immuron Ltd has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is IMRN's fundamental grade?
Based on our AI fundamental analysis in July 2026, Immuron Ltd has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is IMRN stock overvalued or undervalued?
Valuation metrics for IMRN: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is IMRN's AI grade for 2026?
Our dual AI analysis gives Immuron Ltd a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMRN's free cash flow?
Immuron Ltd's operating cash flow is N/A, with capital expenditures of N/A.
How does IMRN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).